Baader Bank Aktiengesellschaft Sells 3,519 Shares of Stryker Corporation $SYK

Baader Bank Aktiengesellschaft lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 14.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,147 shares of the medical technology company’s stock after selling 3,519 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Stryker were worth $7,406,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Providence Capital Advisors LLC raised its position in shares of Stryker by 2.8% in the 3rd quarter. Providence Capital Advisors LLC now owns 14,842 shares of the medical technology company’s stock valued at $5,487,000 after buying an additional 409 shares in the last quarter. Waterway Wealth Management LLC increased its stake in Stryker by 16.0% in the third quarter. Waterway Wealth Management LLC now owns 2,437 shares of the medical technology company’s stock valued at $901,000 after acquiring an additional 336 shares during the last quarter. Wesbanco Bank Inc. raised its position in Stryker by 5.3% during the third quarter. Wesbanco Bank Inc. now owns 33,890 shares of the medical technology company’s stock valued at $12,528,000 after purchasing an additional 1,721 shares in the last quarter. Midwest Trust Co lifted its stake in Stryker by 1.7% during the third quarter. Midwest Trust Co now owns 37,533 shares of the medical technology company’s stock worth $13,875,000 after purchasing an additional 612 shares during the last quarter. Finally, Rockland Trust Co. boosted its holdings in shares of Stryker by 26.1% in the 3rd quarter. Rockland Trust Co. now owns 3,792 shares of the medical technology company’s stock valued at $1,402,000 after purchasing an additional 786 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. The Goldman Sachs Group set a $399.00 price target on Stryker in a report on Friday, January 9th. Barclays reissued an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. TD Cowen downgraded shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target on the stock. in a research note on Monday, January 26th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a report on Tuesday, January 6th. Finally, Sanford C. Bernstein increased their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Twelve research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $426.94.

Stryker Trading Up 1.4%

NYSE SYK opened at $361.20 on Wednesday. The firm has a market capitalization of $138.13 billion, a PE ratio of 43.00, a price-to-earnings-growth ratio of 2.08 and a beta of 0.87. The business’s 50-day moving average price is $357.96 and its two-hundred day moving average price is $369.88. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the prior year, the business posted $4.01 earnings per share. The firm’s revenue was up 11.4% on a year-over-year basis. On average, analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio is presently 41.90%.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 252,118 shares of company stock worth $91,504,172. 5.20% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.